With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
July 6, 2017. A Phase III randomized trial published in Green Journal earlier this year compared treating elective nodal regions in patients with squamous cell carcinoma of any H&N site with EQD2 doses of either the standard 50 Gy vs a de-escalated regimen of 40 Gy. Between the 100 patients randomized to each arm, there were no differences in local, regional or metastatic recurrences with only 2 failures occurring in the 40 Gy volume. Unfortunately, there were also no differences in rates of dysphagia (primary endpoint). But moving beyond 2 years follow-up, we may see a greater divergence in late toxicities without as much concern for persistent disease. And as we learn more about risk-stratification (e.g., HPV and smoking statuses), perhaps we can more appropriately select which patients to place on the dose de-escalator to less toxicity.